Literature DB >> 3708607

Antiemetic studies: a methodological discussion.

I N Olver, R M Simon, J Aisner.   

Abstract

Methodological issues encountered in reviewing the antiemetic literature are discussed. Variables affecting antiemetic assessment include those relating to the patient, the emetic stimulus, and the differences in action of the antiemetic drugs. Study design questions including the desirability of randomization, double blinding, use of controls, and stratifications for factors such as previous exposure to chemotherapy and strength of the emetic stimulus are discussed. From a statistical viewpoint a parallel subject design with adequate sample size is recommended. The problems of standardizing the evaluation of nausea and vomiting are considered and simple ordinal scales grading severity are suggested. The patient's overall assessment of tolerance of therapy is of primary importance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708607

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

1.  Antiemetic study design: desirable objectives, stratifications and analyses.

Authors:  I N Olver
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis.

Authors:  J M Brechot; J P Dupeyron; C Delattre; C Chastang; J P Laaban; J Rochemaure
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.

Authors:  G F Fleming; E E Vokes; J M McEvilly; L Janisch; D Francher; L Smaldone
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting.

Authors:  Kristopher Dennis; Rehana Jamani; Clare McGrath; Leila Makhani; Henry Lam; Patrick Bauer; Carlo De Angelis; Natalie Coburn; C Shun Wong; Edward Chow
Journal:  Support Care Cancer       Date:  2017-03-31       Impact factor: 3.603

Review 5.  Methodological issues in antiemetic studies.

Authors:  M Aapro
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

6.  Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.

Authors:  J Pater; L Slamet; B Zee; D Osoba; D Warr; J Rusthoven
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

7.  Assessment of nausea.

Authors:  A Del Favero; F Roila; C Basurto; V Minotti; E Ballatori; L Patoia; M Tonato; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.

Authors:  J Latreille; D Stewart; F Laberge; P Hoskins; J Rusthoven; E McMurtrie; D Warr; L Yelle; D Walde; F Shepherd
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

Review 9.  Controlling cancer chemotherapy-induced emesis. An update.

Authors:  C Seynaeve; P H De Mulder; J Verweij; R J Gralla
Journal:  Pharm Weekbl Sci       Date:  1991-10-18

10.  Acupuncture prophylaxis of cancer chemotherapy-induced sickness.

Authors:  J W Dundee; R G Ghaly; K T Fitzpatrick; W P Abram; G A Lynch
Journal:  J R Soc Med       Date:  1989-05       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.